Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic Transplants
The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
T cells that accompany allogeneic hematopoietic grafts for treating leukemia enhance engraftment and mediate the graft-versus-leukemia effect. Unfortunately, alloreactive T cells also cause graft-versus-host disease (GVHD). T cell depletion prevents GVHD but increases the risk of graft rejection and leukemic relapse. In human transplants, we show that donor-versus-recipient natural killer (NK)-cell alloreactivity could eliminate leukemia relapse and graft rejection and protect patients against GVHD. In mice, the pretransplant infusion of alloreactive NK cells obviated the need for high-intensity conditioning and reduced GVHD. NK cell alloreactivity may thus provide a powerful tool for enhancing the efficacy and safety of allogeneic hematopoietic transplantation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“NK cells, which act as important immune cells, are widely used for transplantation [82,83].”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [82]
Citations
Cites
Selective rejection of H–2-deficient lymphoma variants suggests alternative immune defence strategy
Kärre, K., Ljunggren, H. G., Piontek, G., & Kiessling, R. (1986) · Nature · doi:10.1038/319675a0 · Cited by 2,161
Lanier, L. L. (1998) · Annual Review of Immunology · doi:10.1146/annurev.immunol.16.1.359 · Cited by 1,648
Prevention of Graft Versus Host Disease by Inactivation of Host Antigen-Presenting Cells
Shlomchik, W. D., Couzens, M. S., Tang, C. B., McNiff, J., Robert, M. E., Liu, J., Shlomchik, M. J., & Emerson, S. G. (1999) · Science · doi:10.1126/science.285.5426.412 · Cited by 1,186
Self-citationAversa, F., Tabilio, A., Velardi, A., Cunningham, I., Terenzi, A., Falzetti, F., Ruggeri, L., Barbabietola, G., Aristei, C., Latini, P., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810223391702 · Cited by 1,168
Self-citationRole of Natural Killer Cell Alloreactivity in HLA-Mismatched Hematopoietic Stem Cell Transplantation
Ruggeri, L., Capanni, M., Casucci, M., Volpi, I., Tosti, A., Perruccio, K., Urbani, E., Negrin, R. S., Martelli, M. F., & Velardi, A. (1999) · Blood · doi:10.1182/blood.v94.1.333.413a31_333_339 · Cited by 994
Self-citationHematopoietic Cell Transplantation
Forman, S. J., & Nakamura, R. (2015) · Blackwell Science Ltd eBooks · Cited by 659
Aversa, F., Tabilio, A., Terenzi, A., Velardi, A., Falzetti, F., Giannoni, C., Iacucci, R., Zei, T., Martelli, M., & Gambelunghe, C. (1994) · Blood · doi:10.1182/blood.v84.11.3948.bloodjournal84113948 · Cited by 576
Self-citationColonna, M., Borsellino, G., Falco, M., Ferrara, G. B., & Strominger, J. L. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.24.12000 · Cited by 460
Megadose of T cell-depleted bone marrow overcomes MHC barriers in sublethally irradiated mice
Bachar-Lustig, E., Rachamim, N., Li, H.-W., Lan, F., & Reisner, Y. (1995) · Nature Medicine · doi:10.1038/nm1295-1268 · Cited by 322
Generation of Allospecific Natural Killer Cells by Stimulation Across a Polymorphism of HLA-C
Colonna, M., Brooks, E. G., Falco, M., Ferrara, G. B., & Strominger, J. L. (1993) · Science · doi:10.1126/science.8493555 · Cited by 234
Research works printed but not linked: 3
- Valiante N. M., Parham P., Biol. Blood Marrow Transplant. 3, 229 (1997).
- A supplementary table and experimental procedures are available on Science Online at www.sciencemag.org/cgi/content/full/295/5562/2097/DC1.
- We thank A. Santucci for statistical analyses L. Romani for critical review of the manuscript and G. Boyd for her essential role in manuscript editing. Supported by grants from the Italian Association for Cancer Research the Italian Ministry of Research and the Italian Ministry of Health and by a translational research grant from the Leukemia and Lymphoma Society. W.D.S. is supported by NIH grant number HL03979.
Cited by
Items 301–400 of 1,002
Chaidos, A., Patterson, S., Szydlo, R., Chaudhry, M. S., Dazzi, F., Kanfer, E., McDonald, D., Marin, D., Milojkovic, D., Pavlu, J., et al. (2012) · Blood · doi:10.1182/blood-2011-11-389304 · Cited by 168
“7 106 cells/kg of body weight 39 (21-57) 11.”
InfluentialJohansson, S., Johansson, M., Rosmaraki, E., Vahlne, G., Mehr, R., Salmon-Divon, M., Lemonnier, F., Kärre, K., & Höglund, P. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050167 · Cited by 164
“Other areas in which our findings are relevant are the use of alloreactive NK cells in graft-versus-leukemia effects after bone marrow transplantation (45) and the involvement of KIR genes in the control of infections and autoimmune diseases (46–48).”
ResultRegulatory T cells in stem cell transplantation: strategies and first clinical experiences
Edinger, M., & Hoffmann, P. (2011) · Current Opinion in Immunology · doi:10.1016/j.coi.2011.06.006 · Cited by 167
“In fact, allogeneic SCT is the most routinely used cellular immunotherapy, since its therapeutic efficacy depends not only on the regeneration of myelopoiesis from stem cells but also – and equally important – on the immunological eradication of residual host hematopoiesis by cotransplanted donor T cells [1] and NK ce…”
BackgroundThe CD94/NKG2 Family of Receptors: From Molecules and Cells to Clinical Relevance
Borrego, F., Masilamani, M., Marusina, A. I., Tang, X., & Coligan, J. E. (2006) · Immunologic Research · doi:10.1385/ir:35:3:263 · Cited by 166
Carlsten, M., Korde, N., Kotecha, R., Reger, R., Bor, S., Kazandjian, D., Landgren, O., & Childs, R. W. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1108 · Cited by 166
Bednarski, J. J., Zimmerman, C., Berrien-Elliott, M. M., Foltz, J. A., Becker-Hapak, M., Neal, C. C., Foster, M., Schappe, T., McClain, E., Pence, P. P., et al. (2022) · Blood · doi:10.1182/blood.2021013972 · Cited by 164
Different checkpoints in human NK-cell activation
MORETTA, L., BOTTINO, C., PENDE, D., VITALE, M., MINGARI, M., & MORETTA, A. (2004) · Trends in Immunology · doi:10.1016/j.it.2004.09.008 · Cited by 166
Natural killer cell immune escape in acute myeloid leukemia
Lion, E., Willemen, Y., Berneman, Z. N., Van Tendeloo, V. F. I., & Smits, E. L. J. (2012) · Leukemia · doi:10.1038/leu.2012.87 · Cited by 164
Ciurea, S. O., Al Malki, M. M., Kongtim, P., Fuchs, E. J., Luznik, L., Huang, X.-J., Ciceri, F., Locatelli, F., Aversa, F., Castagna, L., et al. (2020) · Bone Marrow Transplantation · doi:10.1038/s41409-019-0499-z · Cited by 163
Self-citationUse of Allogeneic NK Cells for Cancer Immunotherapy
Geller, M. A., & Miller, J. S. (2011) · Immunotherapy · doi:10.2217/imt.11.131 · Cited by 162
Natural killer cells and cancer: Regulation by the killer cell Ig-like receptors (KIR)
Purdy, A. K., & Campbell, K. S. (2009) · Cancer Biology & Therapy · doi:10.4161/cbt.8.23.10455 · Cited by 164
Kahl, C., Storer, B. E., Sandmaier, B. M., Mielcarek, M., Maris, M. B., Blume, K. G., Niederwieser, D., Chauncey, T. R., Forman, S. J., Agura, E., et al. (2007) · Blood · doi:10.1182/blood-2007-03-078592 · Cited by 163
“Target antigens for T-cell-mediated graftversus-tumor effects can be ubiquitous polymorphic minor histocompatibility antigens and/or antigens uniquely expressed on hematopoietic cells (hematopoietic antigens),(8,9) although a role for natural killer cells has also been postulated.(10) The current conditioning regimen…”
BackgroundHaploidentical hematopoietic transplantation: current status and future perspectives
Reisner, Y., Hagin, D., & Martelli, M. F. (2011) · Blood · doi:10.1182/blood-2011-07-338822 · Cited by 165
Self-citationRenoux, V. M., Zriwil, A., Peitzsch, C., Michaëlsson, J., Friberg, D., Soneji, S., & Sitnicka, E. (2015) · Immunity · doi:10.1016/j.immuni.2015.07.011 · Cited by 160
“In patients with acute myeloid leukemia, transplanted donor NK cells expressing mismatched inhibitory receptors provided graft versus leukemia effect in the absence of graft versus host disease (Ruggeri et al., 2002).”
BackgroundSarvaria, A., Jawdat, D., Madrigal, J. A., & Saudemont, A. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00329 · Cited by 163
“(4) who reported NK cell alloreactivity against leukemic cells while reducing the risk of graft-versus-host disease (GvHD) in the context of human leukocyte antigen (HLA) mismatch settings.”
BackgroundExploitation of natural killer cells for the treatment of acute leukemia
Handgretinger, R., Lang, P., & André, M. C. (2016) · Blood · doi:10.1182/blood-2015-12-629055 · Cited by 159
NK cell alloreactivity and allogeneic hematopoietic stem cell transplantation
Ruggeri, L., Mancusi, A., Burchielli, E., Capanni, M., Carotti, A., Aloisi, T., Aversa, F., Martelli, M. F., & Velardi, A. (2008) · Blood Cells, Molecules, and Diseases · doi:10.1016/j.bcmd.2007.06.029 · Cited by 161
Self-citationHuman natural killer cells: Form, function, and development
Mace, E. M. (2022) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2022.09.022 · Cited by 190
Giuliani, M., Oudrhiri, N., Noman, Z. M., Vernochet, A., Chouaib, S., Azzarone, B., Durrbach, A., & Bennaceur-Griscelli, A. (2011) · Blood · doi:10.1182/blood-2010-12-325324 · Cited by 158
Effects of anti-NKG2A antibody administration on leukemia and normal hematopoietic cells
Ruggeri, L., Urbani, E., Andre, P., Mancusi, A., Tosti, A., Topini, F., Blery, M., Animobono, L., Romagne, F., Wagtmann, N., et al. (2016) · Haematologica · doi:10.3324/haematol.2015.135301 · Cited by 160
“Haematologica 2016 Volume 101(5):626-633 ARTICLE Cell Therapy & Immunotherapy”
BackgroundInfluentialSelf-citationNoncytotoxic Functions of NK Cells: Direct Pathogen Restriction and Assistance to Adaptive Immunity
Strowig, T., Brilot, F., & Münz, C. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.12.7785 · Cited by 176
CAR-NK Cells: From Natural Basis to Design for Kill
Khawar, M. B., & Sun, H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.707542 · Cited by 172
“This suppression can be prevented by transferring allogeneic or haploidentical NK cells having KIR–ligand mismatch owing to missing-self recognition of tumor cells (35).”
BackgroundPathophysiology of acute graft‐versus‐host disease
Reddy, P. R. (2003) · Hematological Oncology · doi:10.1002/hon.716 · Cited by 157
Searching for alternative hematopoietic stem cell donors for pediatric patients
Rocha, V., & Locatelli, F. (2007) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705963 · Cited by 165
Alloreactive killer cells: hindrance and help for haematopoietic transplants
Parham, P., & McQueen, K. L. (2003) · Nature reviews. Immunology · doi:10.1038/nri999 · Cited by 170
“The beneficial effects of NK-cell alloreactions in patients with AML led Ruggeri et al. to devise mouse models of haploidentical transplantation.”
BackgroundMethodResultInfluentialCarlsten, M., & Järås, M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02357 · Cited by 176
“Hence, these protocols can be used as a bridge to an allogeneic SCT or maybe to deepen responses in the post-consolidation setting, but not cure patients with myeloid malignancies.”
BackgroundInfluentialEngineered off-the-shelf therapeutic T cells resist host immune rejection
Mo, F., Watanabe, N., McKenna, M. K., Hicks, J. M., Srinivasan, M., Gomes‐Silva, D., Atilla, E., Smith, T. S., Atilla, P. A., Ma, R., et al. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0601-5 · Cited by 165
Kim, G. G., Donnenberg, V. S., Donnenberg, A. D., Gooding, W. E., & Whiteside, T. L. (2007) · Journal of Immunological Methods · doi:10.1016/j.jim.2007.05.013 · Cited by 152
Leveraging NKG2D Ligands in Immuno-Oncology
Fuertes, M. B., Domaica, C. I., & Zwirner, N. W. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.713158 · Cited by 165
Brunstein, C. G., Wagner, J. E., Weisdorf, D. J., Cooley, S., Noreen, H. J., Barker, J. N., DeFor, T. E., Verneris, M. R., Blazar, B. R., & Miller, J. S. (2009) · Blood · doi:10.1182/blood-2008-12-197467 · Cited by 150
“Bu containing 1 (2) 8 (7) 1 (3) 1 (1) .”
Shaffer, B. C., Luduec, J.-B. L., Forlenza, C. J., Jakubowski, A. A., Perales, M., Young, J. W., & Hsu, K. C. (2016) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2015.12.028 · Cited by 151
“A second strategy to address relapse is the infusion of unmanipulated 84 donor lymphocytes (DLI) to increase the potential for GVL. DLI results in remission of CML in 85 approximately 70-90%; however, responses are much less frequent in MDS and occur only 86 rarely in AML.”
NK Cell Dysfunction and Checkpoint Immunotherapy
Bi, J., & Tian, Z. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01999 · Cited by 169
“However, strikingly, for those mismatched cases, this number dropped to 0% (98).”
BackgroundShapiro, R. M., Birch, G. C., Hu, G., Cadavid, J. V., Nikiforow, S., Bagińska, J., Ali, A. K., Tarannum, M., Sheffer, M., Abdulhamid, Y. Z., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci154334 · Cited by 163
Developmental Immunology and Role of Host Defenses in Fetal and Neonatal Susceptibility to Infection
Lewis, D. B., & Wilson, C. B. (2006) · Elsevier eBooks · doi:10.1016/b0-72-160537-0/50006-2 · Cited by 157
NK Cells in the Tumor Microenvironment
Guillerey, C. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-49270-0_4 · Cited by 174
Cooley, S., Weisdorf, D. J., Guethlein, L. A., Klein, J. P., Wang, T., Marsh, S. G. E., Spellman, S. R., Haagenson, M. D., Saeturn, K., Ladner, M. B., et al. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1302517 · Cited by 148
“Based on the results of our previous study (2), donors are classified as “Neutral” (none or one KIR B-motifs), “Better” (two or more B motifs without Cen-B/B), or “Best” (two or more B motifs with Cen-B/B) (14).”
Crucitti, L., Crocchiolo, R., Toffalori, C., Mazzi, B. A., Greco, R., Signori, A., Sizzano, F., Chiesa, L., Zino, E., Stanghellini, M. T. L., et al. (2014) · Leukemia · doi:10.1038/leu.2014.314 · Cited by 148
Weisdorf, D. J., Zhang, M., Arora, M., Horowitz, M. M., Rizzo, J. D., & Eapen, M. (2012) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2012.06.014 · Cited by 148
“T cell, natural killer cell, or proapoptotic inflammatory responses may all limit persistence of neoplastic cells, yet not induce clinically uncontrollable or fatal GVHD [13-16].”
Lee, D. A., Denman, C. J., Rondón, G., Woodworth, G. G., Chen, J. J., Fisher, T. D., Kaur, I., Fernández-Viña, M., Cao, K., Ciurea, S. O., et al. (2016) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2016.04.009 · Cited by 157
“NK cells can be selected for increased alloreactivity by mismatch of licensed inhibitory receptors in a setting of missing HLA ligands (KIR receptor:ligand mismatch); these cells may have more potent GVL activity and may also enhance engraftment and reduce GVHD [5] by eliminating host T cells and antigenpresenting cel…”
Markers and function of human NK cells in normal and pathological conditions
del Zotto, G., Marcenaro, E., Vacca, P., Sivori, S., Pende, D., Chiesa, M. D., Moretta, F., Ingegnere, T., Mingari, M., Moretta, A., et al. (2017) · Cytometry. Part B, Clinical cytometry · doi:10.1002/cyto.b.21508 · Cited by 100
“Thanks to this protocol, haplo-HSCT resulted in low percentages ( 10%) of mild (grade I or, rarely grade II) GvHD and high rates of engraftment, in the absence of post-transplant immunosuppression (108,109).”
BackgroundLeung, W. H., Iyengar, R. V., Triplett, B. M., Turner, V., Behm, F. G., Holladay, M., Houston, J., & Handgretinger, R. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.10.6540 · Cited by 148
“” For instance, KIR mismatch was defined by the Perugia group as mismatch between the donor KIR ligand and recipient KIR ligand (4) and by the Nantes group as mismatch between the donor KIR and recipient KIR (7).”
BackgroundHLA-C expression levels define permissible mismatches in hematopoietic cell transplantation
Petersdorf, E. W., Gooley, T. A., Malkki, M., Bacigalupo, A. P., Cesbron, A., du Toit, E. D., Ehninger, G., EGELAND, T., Fischer, G., Gervais, T., et al. (2014) · Blood · doi:10.1182/blood-2014-09-599969 · Cited by 149
Self-citationChapter 2 Natural Killer Cell Tolerance
Jonsson, A. H., & Yokoyama, W. M. (2009) · Advances in immunology · doi:10.1016/s0065-2776(08)01002-x · Cited by 168
A perspective on the selection of unrelated donors and cord blood units for transplantation
Spellman, S. R., Eapen, M., Logan, B. R., Mueller, C. R., Rubinstein, P., Setterholm, M. I., Woolfrey, A. E., Horowitz, M. M., Confer, D. L., & Hurley, C. K. (2012) · Blood · doi:10.1182/blood-2012-03-379032 · Cited by 146
Oevermann, L., Michaelis, S. U., Mezger, M., Lang, P., Toporski, J., Bertaina, A., Zecca, M., Moretta, L., Locatelli, F., & Handgretinger, R. (2014) · Blood · doi:10.1182/blood-2014-03-565069 · Cited by 146
The allogeneic graft‐versus‐cancer effect
Ringdén, O., Karlsson, H., Olsson, R., Omazic, B., & Uhlin, M. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07886.x · Cited by 155
“T-cells are regarded as the main effector cell of the GVL effect, but NK-cells may also contribute (Farag et al, 2002; Ruggeri et al, 2002; Yu et al, 2009).”
BackgroundImmune regulatory cell infusion for graft-versus-host disease prevention and therapy
Blazar, B. R., MacDonald, K. P. A., & Hill, G. R. (2018) · Blood · doi:10.1182/blood-2017-11-785865 · Cited by 153
iPSC-Derived Natural Killer Cell Therapies - Expansion and Targeting
Goldenson, B. H., Hor, P., & Kaufman, D. S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.841107 · Cited by 159
“NK cells are also recognized to play a key role in the anti-tumor activity of allogeneic hematopoietic cell transplantation (25).”
BackgroundDulphy, N., Haas, P., Busson, M., Belhadj, S., de Latour, R. P., Robin, M., Carmagnat, M., Loiseau, P., Tamouza, R., Scieux, C., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.3.2227 · Cited by 156
“Discussion Despite current data showing a strong GVL effect mediated by donor-origin NK cells after transplant (3, 38), the degree of maturity and the functionality of NK cells after allogeneic HSCT remain controversial.”
BackgroundBishara, A., Santis, D. D., Witt, C., Brautbar, C., Christiansen, F., Or, R., Nagler, A., & Slavin, S. (2004) · Tissue Antigens · doi:10.1111/j.0001-2815.2004.00182.x · Cited by 158
The Immunological Paradox of Pregnancy: A Reappraisal
Moffett, A., & Loke, Y. W. (2003) · Placenta · doi:10.1016/s0143-4004(03)00167-x · Cited by 150
Amrolia, P. J., Casadei, G. M., Yvon, E. S., Huls, H. M., Sili, U., Wieder, E., Bollard, C. M., Michálek, J., Ghetie, V. F., Heslop, H. E., et al. (2003) · Blood · doi:10.1182/blood-2002-11-3516 · Cited by 146
Mikulak, J., Bruni, E., Oriolo, F., Di Vito, C., & Mavilio, D. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00946 · Cited by 145
“Adoptive NK cell transfer therapies have been first introduced to improve the clinical outcome of patients affected by hematologic malignancies and undergone allogeneic hematopoietic stem cell transplantation (allo-HSCT) (146, 147).”
BackgroundSuccessful adoptive transfer and in vivo expansion of haploidentical γδ T cells
Wilhelm, M., Smetak, M., Schaefer‐Eckart, K., Kimmel, B., Birkmann, J., Einsele, H., & Kunzmann, V. (2014) · Journal of Translational Medicine · doi:10.1186/1479-5876-12-45 · Cited by 155
“natural killer (NK) cell alloreactivity in haploidentical transplantations, through a “missing self-recognition” in patients with AML [1].”
BackgroundInfluentialUtilizing Cytokines to Function-Enable Human NK Cells for the Immunotherapy of Cancer
Romee, R., Leong, J. W., & Fehniger, T. A. (2014) · Scientifica · doi:10.1155/2014/205796 · Cited by 164
“NK cells have increasingly been recognized as important contributors to the graft-versus-leukemia effect following allogeneic HSCT, where MHC haploidentical NK cells were identified as alloreactive to myeloid leukemia blasts that lacked the corresponding HLA ligand for at least one KIR receptor and were associated wit…”
BackgroundLocatelli, F., Pende, D., Falco, M., Della Chiesa, M., Moretta, A., & Moretta, L. (2018) · Trends in Immunology · doi:10.1016/j.it.2018.04.009 · Cited by 146
Malmberg, K. (2004) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-004-0577-x · Cited by 169
“Similar mechanisms may account for the curing potential of the graft-versus-leukemia (GVL) effect seen in BMT against acute leukemias.”
BackgroundInfluentialOff-the-shelf cell therapy with induced pluripotent stem cell-derived natural killer cells
Sætersmoen, M., Hammer, Q., Valamehr, B. B., Kaufman, D. S., & Malmberg, K. (2018) · Seminars in Immunopathology · doi:10.1007/s00281-018-0721-x · Cited by 156
Dissecting the biology of allogeneic HSCT to enhance the GvT effect whilst minimizing GvHD
Blazar, B. R., Hill, G. R., & Murphy, W. J. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0356-4 · Cited by 158
The clinical landscape of CAR NK cells
Jørgensen, L. V., Christensen, E. B., Barnkob, M. B., & Barington, T. (2025) · Experimental Hematology and Oncology · doi:10.1186/s40164-025-00633-8 · Cited by 164
Kuball, J. H. E., Schmitz, F., Voss, R.-H., Ferreira, E. A., Engel, R., Guillaume, P., Strand, S., Romero, P. J., Huber, C., Sherman, L. A., et al. (2005) · Immunity · doi:10.1016/j.immuni.2004.12.005 · Cited by 157
Koehl, U., Brehm, C., Huenecke, S., Zimmermann, S. Y., Kloeß, S., Bremm, M., Ullrich, E., Soerensen, J., Quaiser, A., Erben, S., et al. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00118 · Cited by 152
Lima, M. J. G. D., Porter, D. L., Battiwalla, M., Bishop, M., Giralt, S., Hardy, N. M., Kröger, N. M., Wayne, A. S., & Schmid, C. (2013) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2013.08.012 · Cited by 144
Bray, R. A., Hurley, C. K., Kamani, N. R., Woolfrey, A. E., Müller, C., Spellman, S. R., Setterholm, M. I., & Confer, D. L. (2008) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2008.06.014 · Cited by 142
Li, L., Liu, L. N., Feller, S., Allen, C., Shivakumar, R., Fratantoni, J., Wolfraim, L. A., Fujisaki, H., Campana, D., Chopas, N., et al. (2010) · Cancer Gene Therapy · doi:10.1038/cgt.2009.61 · Cited by 144
DNAM‐1 control of natural killer cells functions through nectin and nectin‐like proteins
de Andrade, L. F., Smyth, M. J., & Martinet, L. (2014) · Immunology & Cell Biology · doi:10.1038/icb.2013.95 · Cited by 142
Sun, J. C., Beilke, J. N., Bezman, N. A., & Lanier, L. L. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20100479 · Cited by 144
“In addition, the adoptive transfer of activated human NK cells has been used in the treatment of certain cancers (Ruggeri et al., 2002; Hsu et al., 2005; Miller et al., 2005, 2007; Passweg et al., 2005; Shi et al., 2008; Cooley et al., 2009; Gill et al., 2009; Moretta et al., 2010; Rubnitz et al., 2010).”
BackgroundCooley, S., Parham, P., & Miller, J. S. (2018) · Blood · doi:10.1182/blood-2017-08-752170 · Cited by 126
Minimal PD-1 expression in mouse and human NK cells under diverse conditions
Judge, S. J., Dunai, C., Aguilar, E. G., Vick, S. C., Sturgill, I. R., Khuat, L. T., Stoffel, K. M., Dyke, J. V., Longo, D. L., Darrow, M. A., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci133353 · Cited by 151
“Since NK cells have a strong correlation with responses in hematologic malignancies (15), we next assessed NK activity and PD-1 expression in vivo in mice using the murine acute myelogenous leukemia cell line C1498.”
Next-generation cell therapies: the emerging role of CAR-NK cells
Başar, R., Daher, M., & Rezvani, K. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002547 · Cited by 152
Cieri, N., Greco, R., Crucitti, L., Morelli, M., Giglio, F., Levati, G. V., Assanelli, A. A., Carrabba, M. G., Bellio, L., Milani, R., et al. (2015) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2015.04.025 · Cited by 141
Natural Killer Cells in Cancer Immunotherapy
Miller, J. S., & Lanier, L. L. (2019) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030518-055653 · Cited by 137
“This finding, consistent with pioneering work by Velardi and colleagues (Ruggeri et al. 2002) showing that NK cell alloreactivity after haploidentical transplantation can control myeloid leukemias, sparked the hypothesis that use of allogenic NK cell therapies from healthy donors might increase the…”
ResultBethge, W. A., Faul, C., Bornhäuser, M., Stuhler, G., Beelen, D. W., Lang, P., Stelljes, M., Vogel, W., Haegele, M., Handgretinger, R., et al. (2007) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2007.07.001 · Cited by 140
Targeting myeloid-derived suppressor cells to enhance natural killer cell-based immunotherapy
Joshi, S., & Sharabi, A. B. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108114 · Cited by 154
“However, a very limited anti-tumor effect was observed due to the limited activation of NK cells (Ruggeri et al., 2002).”
BackgroundThe changing role of natural killer cells in solid organ rejection and tolerance.
Kitchens, W., Uehara, S., Chase, C., Colvin, R., Russell, P., & Madsen, J. (2006) · Transplantation · doi:10.1097/01.tp.0000202844.33794.0e · Cited by 143
“This effect has contributed to a dramatic increase in the rate of sustained remission in patients with acute myelogenous leukemia (31, 32).”
BackgroundRole of KIR ligand incompatibility in hematopoietic stem cell transplantation using unrelated donors
Bornhäuser, M., Schwerdtfeger, R., Martin, H., Frank, K., Theuser, C., & Ehninger, G. (2004) · Blood · doi:10.1182/blood-2003-11-3893 · Cited by 140
Cancer Immunotherapy: Accomplishments to Date and Future Promise
Helmy, K. Y., Patel, S. A., Nahas, G. R., & Rameshwar, P. (2013) · Therapeutic Delivery · doi:10.4155/tde.13.88 · Cited by 156
Emerging concepts in haematopoietic cell transplantation
Li, H. W., & Sykes, M. (2012) · Nature reviews. Immunology · doi:10.1038/nri3226 · Cited by 143
Human Natural Killer Cells: Origin, Receptors, Function, and Clinical Applications
Moretta, L., Montaldo, E., Vacca, P., Del Zotto, G., Moretta, F., Merli, P., Locatelli, F., & Mingari, M. C. (2014) · International Archives of Allergy and Immunology · doi:10.1159/000365632 · Cited by 140
Sánchez-Correa, B., Morgado, S., Gayoso, I., Bergua, J., Casado, J., Arcos, M. J., Bengochea, M., Durán, E., Solana, R., & Tarazona, R. (2011) · Cancer Immunology and Immunotherapy · doi:10.1007/s00262-011-1050-2 · Cited by 127
“The expression of HLA class I molecules on AML blasts may protect them from NK cell-mediated lysis and explain why the incompatibility between the recipient’s HLA class I antigens and the KIR repertoire expressed by the donor NK cells shows beneficial anti-tumour effects in hematopoietic transplantation of patients wi…”
Koehl, U., Sörensen, J., Esser, R., Zimmermann, S. Y., Grüttner, H. P., Tonn, T., Seidl, C., Seifried, E., Klingebiel, T. E., & Schwabe, D. (2004) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2004.08.013 · Cited by 139
Curti, A., Ruggeri, L., Parisi, S., Bontadini, A., Dan, E., Motta, M. R., Rizzi, S., Trabanelli, S., Očadlíková, D., Lecciso, M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1604 · Cited by 156
“These data are in line with previous reports in themousemodel, where escalated doses of human alloreactiveNK cells are associatedwith increased antileukemia effect, leading to leukemia eradication (9).”
ResultSelf-citationWang, H., Grzywacz, B. J., Sukovich, D. J., McCullar, V., Cao, Q., Lee‐Sherick, A. B., Blazar, B. R., Cornfield, D. N., Miller, J. S., & Verneris, M. R. (2007) · Blood · doi:10.1182/blood-2006-10-048173 · Cited by 146
“Both murine and human studies show that NK cells mediate a number of potentially beneficial functions following allo-HCT including: eliminating residual malignant cells, removal of host antigen presenting cells (thereby reducing GVHD), and mediating immunity to viral pathogens directly through the cytolyisis of virall…”
BackgroundResultNew approaches for preventing and treating chronic graft-versus-host disease
Lee, S. J. (2005) · Blood · doi:10.1182/blood-2004-10-4023 · Cited by 139
Interleukin-15 enhances immune reconstitution after allogeneic bone marrow transplantation
Alpdoğan, Ö., Eng, J. M., Muriglan, S. J., Willis, L. M., Hubbard, V. M., Tjoe, K. H., Terwey, T. H., Kochman, A. A., & van den Brink, M. R. M. (2004) · Blood · doi:10.1182/blood-2003-09-3344 · Cited by 141
Zhang, T., Wu, M.-R., & Sentman, C. L. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1103495 · Cited by 139
“NK cells have demonstrated improved clinical outcomes in patients with acute myeloid leukemia when there has been a mismatch between donor NK cells and host MHC molecules (35, 36).”
BackgroundBoudreau, J. E., Giglio, F., Gooley, T. A., Stevenson, P. A., Le Luduec, J.-B., Shaffer, B. C., Rajalingam, R., Hou, L., Hurley, C. K., Noreen, H., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.7059 · Cited by 137
Nalle, S. C., & Turner, J. R. (2015) · Mucosal Immunology · doi:10.1038/mi.2015.40 · Cited by 151
“However, it was only recently demonstrated that MHC-mismatched donor NK cells could effectively carry out a graft-versus-leukemia response while causing very little GVHD.(146) The initial explanation for the NK cell-mediated reduction in GVHD was direct killing of host-derived antigenpresenting cells.”
BackgroundNK Cell-Based Immunotherapies in Cancer
Shin, M. H., Kim, J., Lim, S. A., Kim, J. H., Kim, S., & Lee, K. (2020) · Immune Network · doi:10.4110/in.2020.20.e14 · Cited by 147
“between KIR receptors and their ligands expressed on the surface of target tumor cells in hematopoietic stem cell transplants (HSCT) has been demonstrated to induce potent antitumor activity and to limit graft-versus-host disease (GvHD) (50,51).”
BackgroundMacDonald, K. P. A., Rowe, V., Clouston, A. D., Welply, J. K., Kuns, R. D., Ferrara, J. L. M., Thomas, R., & Hill, G. R. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.4.1841 · Cited by 137
“Thus, GVL effects were preserved after the administration of GM cells despite the attenuation of GVHD.”
BackgroundInfluentialChoi, I., Yoon, S. R., Park, S.-Y., Kim, H., Jung, S.-J., Jang, Y. J., Kang, M., Yeom, Y. I., Lee, J., Kim, D., et al. (2014) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2014.01.031 · Cited by 146
Porter, D., Alyea, E. P., Antin, J. H., Lima, M. J. G. D., Estey, E. H., Falkenburg, J. H. F., Hardy, N. M., Kröger, N. M., Leis, J. F., Levine, J. E., et al. (2010) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2010.08.001 · Cited by 139
“Following highly encouraging findings from the Perugia group demonstrating a strong protective effect of donor NK cells on AML relapse in the T-cell depleted haploidentical transplant setting [70], several groups have explored the role of anti-leukemic effects of NK cells in other alloHSCT settings.”
BackgroundLiu, P., Chen, L., & Zhang, H. (2018) · Journal of Immunology Research · doi:10.1155/2018/1206737 · Cited by 137
Human NK cells: From development to effector functions
Arachchige, A. S. P. M. (2020) · Innate Immunity · doi:10.1177/17534259211001512 · Cited by 162
“Thus, mAb therapy, coupled with adoptive autologous NK transfer, seems to be an attractive solution.137 Furthermore, to solve this researchers also began to investigate the possibility of using human allogeneic NKs that have proven themselves to be effective by inducing potent anti-tumor activity and, unlike T cells,…”
BackgroundVelardi, A., Ruggeri, L., Mancusi, A., Aversa, F., & Christiansen, F. (2009) · Current Opinion in Immunology · doi:10.1016/j.coi.2009.07.015 · Cited by 137
Self-citationLaport, G. G., Sheehan, K., Baker, J. B., Armstrong, R. J., Wong, R. M., Lowsky, R., Johnston, L., Shizuru, J. A., Miklos, D. B., Arai, S., et al. (2011) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2011.05.012 · Cited by 134
The Graft-Versus-Leukemia Effect in AML
Sweeney, C., & Vyas, P. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01217 · Cited by 172
“(161), who studied 57 transplanted AML patients and showed that KIR ligand incompatibility in the graft-vs.”
BackgroundMcQueen, K. L., Dorighi, K. M., Guethlein, L. A., Wong, R. M., Sanjanwala, B. M., & Parham, P. (2007) · Human Immunology · doi:10.1016/j.humimm.2007.01.019 · Cited by 141
“The reported benefit of alloreactive NK cells for haploidentical transplant recipients [2-4] stimulated retrospective immunogenetic analysis in the HLA-mismatched transplant setting, where alloreactions due to KIR-ligand mismatch were expected to occur [32,33].”
BackgroundInfluentialNatural Killer Cells and Solid Tumors
Stojanovic, A., & Cerwenka, A. (2011) · Journal of Innate Immunity · doi:10.1159/000325465 · Cited by 146
“Mouse models of spontaneously arising tumors allow a more accurate analysis of the dynamics and kinetics of NK cell antitumor responses. In these models, NK cells face small numbers of transformed cells in the early phase of tumor development and tumor progression more closely resembles the development of solid human…”
BackgroundFoley, B. A., Cooley, S., Verneris, M. R., Curtsinger, J., Luo, X., Waller, E. K., Weisdorf, D. J., & Miller, J. S. (2011) · Blood · doi:10.1182/blood-2011-04-347070 · Cited by 149
Metadata
- Authors
- Ruggeri, L., Capanni, M., Urbani, E., Perruccio, K., Shlomchik, W. D., Tosti, A., Posati, S., Rogaia, D., Frassoni, F., Aversa, F., Martelli, M. F., & Velardi, A.
- Affiliations
- University of Perugia (IT)
- Yale University (US)
- Department of Clinical and Experimental Medicine, Section of Hematology and Clinical Immunology, Perugia University School of Medicine, Perugia, Italy.
- Ospedale Policlinico San Martino (IT)
- ORCID
- Venue
- Science
- Published
- 2002-03-15
- Volume
- 295
- Issue
- 5562
- Pages
- 2097-2100
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2147068163
- Cited by
- 3,380
- References
- 21
- Citations by year
- 2026: 46 · 2025: 92 · 2024: 112 · 2023: 134 · 2022: 157 · 2021: 156 · 2020: 139 · 2019: 155 · 2018: 140 · 2017: 157 · 2016: 152 · 2015: 171 · 2014: 134 · 2013: 162 · 2012: 150
- FWCI
- 63.86
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Heart, Lung, and Blood Institute (HL03979)
- Topics
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Keywords
- natural killer cells, NK cell alloreactivity, allogeneic hematopoietic stem cell transplantation, mismatched transplantation, graft-versus-host disease, graft rejection, leukemia relapse, T cell depletion, conditioning intensity, leukemia
- MeSH terms
- Acute Disease, Animals, Antigen-Presenting Cells, Graft Survival, Graft vs Host Disease, H-2 Antigens, Haplotypes, Histocompatibility Testing, Humans, Killer Cells, Natural, Leukemia, Myeloid, Mice, Inbred Strains, Receptors, Immunologic, Recurrence, T-Lymphocytes, Bone Marrow Transplantation, Mice, SCID, Mice, Inbred NOD, Hematopoietic Stem Cell Transplantation, Disease-Free Survival, Transplantation Conditioning, Graft vs Leukemia Effect, Mice, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Receptors, KIR
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.